Warner Chilcott Plc (NASDAQ:WCRX) reported that its Q1 of 2013 GAAP net income was $113M, or $0.45 a share, unchanged from previous year.
The cash net income or CNI, for the quarter was $231M, in contrast to $249M in the previous year quarter. Adjusted CNI was $232M in the quarter, a lower of $59M, or 20 percent, in contrast to adjusted CNI of $291M in the previous year quarter.
The total revenue for the quarter dropped to $593M, from $685M in the year before quarter.
The analysts polled by Thomson Reuters anticipated the firm to announce earnings of $0.85 a share on revenues of $588.06M. Analysts’ predicts typically exclude special items.
Moving readers toward the broader market, let’s consider percentage change in stocks prices of other stocks in the similar sector who contribute major role in the market that includes Amarin Corporation plc (ADR) (NASDAQ:AMRN) rose +6.15%, DURECT Corporation (NASDAQ:DRRX) edged down -33.96%, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) which also increased +0.05% and Allergan, Inc. (NYSE:AGN) closed up +1.00%.
Warner Chilcott Plc (NASDAQ:WCRX) stock’s trade at beginning with a price of $15.01 and throughout the trading session climbed at a high of $19.41 other than when day-trade ended the stock finally advanced +19.99% to $18.01.
The stock is going forward its 52 week low with 65.99% and looking forward from its 52 week high price with 9.04%. WCRX last month stock price volatility remained 4.12%.
WCRX stock institutional ownership remained 97.42% while insider ownership included 1.37%. In its share capital WCRX has 250.76 million outstanding shares among them 245.46 million shares have been floated in market exchange.
Company’s beta coefficient included 1.05. Beta factors measures the amount of market risk associated with market trade.
Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Entire Disclaimer Here